Molecular profiling of exosomes from multiple sclerosis B cells
Molecular profiling of exosomes from multiple sclerosis B cells
批准号:
10040973
负责人:
AMIT BAR-OR
金额:
$44.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-15 至 2023-06-30
关键词:
AffectApoptosisAxonB-LymphocytesBiologyCell physiologyCerebrospinal FluidCerebrumCessation of lifeCognitiveComplementCorrelation StudiesDataData SetDevelopmentDiseaseDisease ProgressionFacilities and Administrative CostsFunctional disorderFutureGoalsHealthImmune systemImmunoglobulin GImmunoglobulin MImmunoglobulinsIn VitroIncomeIndividualInjuryLeadLesionLipidsMediatingMedicalMeningesMicroRNAsMolecularMolecular ProfilingMultiple SclerosisMultiple Sclerosis LesionsNeuronsOligodendrogliaOutcomePathogenesisPathologicPathway AnalysisPathway interactionsPatientsPennsylvaniaPeripheralPhasePhenotypeProductionProgressive DiseaseProteinsProteomicsRNAResearchRoleSamplingSystems BiologyTestingTherapeuticToxic effectUniversitiescostcytokinecytotoxicdisabilityexosomeexperienceextracellular vesiclesgray matterhigh rewardhigh riskinnovationinsightmultiple omicsmultiple sclerosis patientnew therapeutic targetpreventprotein Brelease factorremyelinationrepairedtranscriptome sequencingvesicular release
中文摘要
项目总结/文摘
英文摘要
Project Summary/Abstract
B cells are central to the pathogenesis of multiple sclerosis (MS), including B cell functions unrelated to
production of immunoglobulins (Ig). Injury to gray matter (GM), particularly subpial GM, is a pathologic
substrate of the progressive stages of MS, with cognitive and physical worsening experienced by many
patients. Our hypothesis is that B cells from the peripheral immune system enter the spinal fluid and
meninges, and release non-immunoglobulin (Ig) factors that injure oligodendroglia (OL) and neurons/axons in
underlying cerebral cortical gray matter (GM) and slowly evolving perivascular lesions. Our research teams at
Wayne State University and the University of Pennsylvania are collaborating to investigate this hypothesis.
Supernatants (Sup) obtained from cultures of circulating B cells from MS patients are cytotoxic to both OL and
neurons in vitro; those from normal controls (NC) show little or no toxicity (Lisak et al. 2012, 2017). Killing is
independent of complement, and does not correlate with Sup levels of IgG, IgM or any single or combination of
a large number of soluble cytokines and other proteins. Death of OL and neurons involves apoptosis and is
caused by one or more factors in the >300 kDa fraction of MS B cell Sup (Lisak et al. 2017). We recently
discovered that the OL toxicity is found in exosome-enriched (Ex-En) extracellular vesicles (EVs) released by
the B cells from patients with MS (Benjamins et al. 2019). We will identify candidate factor/s using proteomics,
RNASeq and lipidomics. Blocking the production or action of the factor/s could decrease OL and neuronal
damage in cortical MS lesions and thus prevent progressive disease and enhance capacity for remyelination
and axonal protection. Anticipated new outcomes include (1) comprehensive molecular profiling and
characterization of Ex-En EVs released by MS B cells, which has not been done before, and (2)
identification of factors in or on the Ex-En EVs that could mediate the damage induced by B cells in
cortical lesions in MS. The integrated multiple -omics approaches we propose will generate rich datasets that
will provide insight into the fundamental biology of B cell EVs as well as the differences in B cell EV phenotype
and function in MS patients compared to NC. This project is significant because of its strong potential for
identifying new targets and strategies to decrease damage and promote repair of the CNS in patients with MS.
This B cell toxicity may be particularly relevant to non-relapsing progressive pathophysiology – a major unmet
therapeutic need. Our project is innovative because the function, components and roles of Ex-En EVs
released by MS B cells have not been previously investigated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of Pennsylvania Clinical Autoimmunity Center of Excellence
-
批准号:10614494
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2019
-
负责人:AMIT BAR-OR
-
依托单位:
University of Pennsylvania Clinical Autoimmunity Center of Excellence
-
批准号:10386830
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2019
-
负责人:AMIT BAR-OR
-
依托单位:
University of Pennsylvania Clinical Autoimmunity Center of Excellence
-
批准号:9918249
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2019
-
负责人:AMIT BAR-OR
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: